BOSTON SCIENTIFIC CORP — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Boston Scientific reported Q3 2026 net sales of $5.138B (1.5% growth YoY), with GAAP EPS of $0.40 (down from $0.51) and adjusted EPS of $0.73 (down from $0.75). The company cited a cybersecurity incident (first reported August 26, 2026) as a major headwind affecting operations. Management lowered FY2026 guidance to 3.75% organic growth and $3.16–$3.18 adjusted EPS; Q4 is expected to decline 3.0–1.0% YoY. Key approvals include FDA 510(k) clearances for kidney-stone and peripheral-artery devices, and a strategic collaboration with HeartFlow for AI-guided coronary intervention planning.
Why this rating
Cybersecurity disruption materially slowed growth; guidance cut signals sustained operational damage. Relative to $158.7B market cap, the ~$5B quarterly revenue and modest margin pressure represent moderate business impact, not transformational. Guidance reduction is material but recovery appears underway.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.